Eupraxia Pharmaceuticals Inc
TSX:EPRX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Eupraxia Pharmaceuticals Inc
TSX:EPRX
|
CA |
|
Compass Pathways PLC
NASDAQ:CMPS
|
UK |
|
Armstrong Flooring Inc
OTC:AFIIQ
|
US |
|
Eltel AB
STO:ELTEL
|
SE |
|
Surgery Partners Inc
NASDAQ:SGRY
|
US |
|
Ourgame International Holdings Ltd
HKEX:6899
|
CN |
|
IVF Hartmann Holding AG
LSE:0QQM
|
CH |
|
Reece Ltd
ASX:REH
|
AU |
|
Solar A/S
CSE:SOLAR B
|
DK |
|
J
|
Jonjee Hi-tech Industrial and Commercial Holding Co Ltd
SSE:600872
|
CN |
|
Sorrento Therapeutics Inc
OTC:SRNE
|
US |
|
Nexteer Automotive Group Ltd
HKEX:1316
|
US |
|
C
|
Cloudwalk Technology Co Ltd
SSE:688327
|
CN |
|
Safehold Inc
NYSE:SAFE
|
US |
|
Lu Thai Textile Co Ltd
SZSE:000726
|
CN |
|
S
|
Sinosoft Technology Group Ltd
HKEX:1297
|
CN |
|
Indo Tambangraya Megah Tbk PT
IDX:ITMG
|
ID |
|
China Telecom Corp Ltd
SSE:601728
|
CN |
|
Shanghai Highly Group Co Ltd
SSE:600619
|
CN |
Eupraxia Pharmaceuticals Inc
Eupraxia Pharmaceuticals, Inc. operates as a drug delivery technology company in Canada. The company is headquartered in Victoria, British Columbia. The company went IPO on 2021-03-09. The firm's lead product candidate EP-104IAR, is developed for the treatment long-lasting pain relief for knee osteoarthritis (OA). In addition to EP-104IAR, Eupraxia is developing a pipeline of earlier-stage long-acting formulations. The firm's pipeline candidates include a range of drugs for indications such as post-surgical anesthetic (EP-105) and post-surgical site infections (EP-201). The firm is also engaged in the development of candidates to its pipeline including an internally developed oncology product. The firm is also engaged in developing a formulation of EP-104IAR for use in canine and equine OA.
Eupraxia Pharmaceuticals, Inc. operates as a drug delivery technology company in Canada. The company is headquartered in Victoria, British Columbia. The company went IPO on 2021-03-09. The firm's lead product candidate EP-104IAR, is developed for the treatment long-lasting pain relief for knee osteoarthritis (OA). In addition to EP-104IAR, Eupraxia is developing a pipeline of earlier-stage long-acting formulations. The firm's pipeline candidates include a range of drugs for indications such as post-surgical anesthetic (EP-105) and post-surgical site infections (EP-201). The firm is also engaged in the development of candidates to its pipeline including an internally developed oncology product. The firm is also engaged in developing a formulation of EP-104IAR for use in canine and equine OA.
